ClinicalTrials.gg
Active, not recruitingNCT05748873PRODYGYUpdated May 15, 2026

Promising ROd-cone DYstrophy Gene therapY

A Phase 1/2 interventional study of SPVN06 in Retinitis Pigmentosa, sponsored by SparingVision. Active, not recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by SparingVision · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 43 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.

Enrollment
22nd of 78
33 · median 21
Started
2023
with 4 others
Phase 1/2
20 of 119
4 open now
Primary completion
2027-02
later than 14 of 41 live
Registered
101st of 119
by date

Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 22nd largest by enrollment of the 78 interventional ones that give a count, is one of 5 that started in 2023, is one of 20 in phase 1/2, reaches primary completion later than 14 of the 41 other live ones, and was the 101st registered.

Retinitis Pigmentosa

281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Retinitis Pigmentosa studies recruiting now, 38 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Retinitis Pigmentosa with a site in United States, or all of them as a file.
02

Study summary

This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene (Step 1), or in any RCD-causative gene (Step 2).

03

Conditions studied

  • Retinitis Pigmentosa

Keywords

  • RHO
  • PDE6A
  • PDE6B
  • Pathogenic Mutation
  • Retinal Disease
  • Eye Disease
  • Rod-Cone Dystrophy
  • Gene Therapy
  • Retinal Dystrophies
  • Retinal Degeneration
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be eligible to participate in this study only if all the following criteria apply:

  1. Able to give signed and comply with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  2. Age ≥18 years at the time of ICF signature.
  3. Subjects of either gender previously diagnosed with advanced RCD due to: in Step 1, biallelic mutations in the rod cGMP phosphodiesterase 6 beta (PDE6B) or rod cGMP phosphodiesterase alpha (PDE6A) genes, or a monoallelic dominant mutation in the rhodopsin (RHO) gene; in Step 2, mutations in any RCD-causative gene (such as variants classified as 'pathogenic/likely pathogenic'). The genotyping results must be documented before the initiation of the Screening Visit. Subjects should be retested by the investigator if their genotyping tests were not performed within the 7 previous years, or if they were not performed by an accredited laboratory.
  4. Advanced stage is defined as a stage of the natural history of the disease where both distance visual acuity and visual field are affected in both eyes. The Study Eye should meet the definition of one of the following substages within the advanced stage (monocular measurements, horizontal axis of isopter III4e for the visual field):

    • Severe stage is defined by both a BCVA below or equal to 20/200 and above or equal to 20/800, and a visual field below or equal to 20 degrees (subjects of Cohorts 1 to 3)
    • Intermediate stage is defined by both a BCVA below or equal to 20/40 and above or equal 20/200, and a visual field below or equal to 30 degrees (subjects of Cohorts 4 to 6)
  5. For subjects with severe advanced RCD enrolled in Step 1 only, the difference in visual acuity between the two eyes of a given subject should be equal to or below 0.3 logarithm of the minimal angle (LogMAR) (≤3 ETDRS lines), with a tolerance margin of 3 ETDRS letters.
  6. Clinical diagnosis of RCD based on past medical and family history, mid-peripheral visual field dysfunction, photopsia, night blindness (nyctalopia), and fundoscopic appearance (including but not restricted to bone spicule pigmentation, attenuation of the retinal vessels, and waxy pallor of the optic nerve).
  7. Diagnosis of RCD is confirmed on prior full-field ERG (any previously performed ERG is acceptable).
  8. Documented preservation of cone inner and outer segments considered good enough by the investigator for the subject to be included in the study.
  9. Negative serum pregnancy test for women of (please refer to Schedule of Assessments for details).
  10. Women of childbearing potential (WOCBP) and men and/or their partner(s) of childbearing potential must agree to use a highly effective method. This applies to the time period between ICF signature and 12 months after SPVN06 subretinal injection SRI (i.e., no longer applicable to subjects of Cohort 4 after randomization). The definition of highly effective contraceptive methods follows CTFG recommendations. Highly effective contraceptive methods are limited to:

    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

      • Oral
      • Intravaginal
      • Transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation:

      • Oral
      • Injectable
      • Implantable
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Vasectomized partner
    • Sexual abstinence
  11. Subjects must be affiliated to a health security system, if they are included in a clinical site based in France (per law).
  12. No out-of-range values for clinical laboratory tests, however, if outside, must be considered as non- by the investigator using a multidisciplinary approach and compatible with a participation in the clinical study.
  13. 12-lead within normal limits, however, when outside, must be documented by the investigator using a multidisciplinary approach as not clinically relevant and compatible with a participation in the clinical study. Nota bene: This criterion of eligibility is only applicable to subjects assigned to a treatment cohort (Cohorts 1, 2, 3, 5, or 6), and is not required to authorize randomization in Step 2.
  14. Physical examination without any clinical findings of clinical relevance (per medical/anesthesia staffs judgment) that could compromise participation in the clinical study or could affect the collection and/or evaluation of the study parameters. The findings of clinical relevance considered as to SPVN06 treatment include, but are not limited to, pulmonary pathology such as , asthma, cardiac conditions such as congestive heart failure or valve disease, renal issues such as renal insufficiency and endocrine issues such as diabetes.

Exclusion criteria

Exclusion Criteria:

Subjects are not eligible to participate in this study if any of the following criteria apply:

  1. Subjects with prior administration of any gene therapy or any previous treatment with stem cell therapy for ocular or non-ocular disease.
  2. Subjects participating in another clinical trial and receiving an medicinal product (IMP) within 5 half-lives or 90 days prior to the injection of SPVN06.
  3. Subjects with systemic disease or other pathology not related to their diagnosis of RCD, and whose symptoms or associated treatments may affect vision, for example cancers or pathology of the central nervous system.
  4. Subjects with narrow irido-corneal angles or any other medical situation contraindicating pupillary dilation.
  5. Subjects known to be allergic to any of the delivery vehicle constituents or to any other drugs planned to be used during the clinical study.
  6. Subjects with known allergies to , or who will be unable to tolerate the corticosteroid regimen as described in the protocol
  7. Subjects with systemic disease or other medical or psychiatric conditions that preclude safe participation in the study.
  8. Subjects receiving therapies, other than the immune modulating regimen described in this protocol, or any other therapy known to influence the immune system including but not limited to steroid implants, cytostatics, interferons, tumor necrosis factor (TNF)-binding proteins, drugs acting on immunophilins, or antibodies with known impact on the immune system.
  9. Subjects of unwilling to use effective starting right after ICF signature and for 12 months after SPVN06 SRI (i.e., no longer applicable to subjects of Cohort 4 after randomization).
  10. Subjects who are pregnant or breastfeeding.
  11. Subjects who are unwilling or unable (based on the investigator's judgment) to comply with the study protocol.
  12. Subjects with any condition that would not allow them to complete follow-up examinations during the study and, in the opinion of the investigator, would make them unsuitable for the study.
  13. Subjects positive for (HIV) or any other systemic immunocompromising disease.
  14. Subjects who have undergone, within 6 months before inclusion, any significant ocular surgery (per investigator's judgment) that could interfere with the evaluation of SPVN06 study objectives.
  15. Presence of eye disorders that could interfere with the assessment of visual acuity and/or any other ocular assessments, including SD-OCT, during the study.
  16. Presence of any systemic or ocular diseases, other than non-syndromic retinitis pigmentosa (RP), that can cause vision loss.
  17. Prior full core vitrectomy or vitreomacular surgery in the Study Eye.
  18. Presence of vitreomacular adhesion or traction, epiretinal membrane macular pucker or macular hole, evident by ophthalmoscopy and/or SD-OCT examinations and assessed by the investigator to significantly affect central vision.
  19. Current evidence of retinal detachment assessed by the investigator to significantly affect central vision.
  20. Active ocular inflammation or recurrent history of idiopathic or -associated uveitis.
  21. Subjects with presence of any suspected or active ocular or periocular infection (conjunctivitis, keratitis, scleritis, endophthalmitis).
  22. Subjects with history of glaucoma.
  23. Subjects with uncontrolled intraocular pressure (IOP).
  24. Subjects with active cancer or currently receiving any therapy for cancer treatment.
  25. Subjects with any history of ocular .
  26. Subjects with a cardiac disease on routine clinical examination (history, physical examination), or known congestive heart failure, myocardial infarction, clinically significant valvular heart disease, clinically significant cardiac rhythm or conduction abnormalities.
  27. Subjects with unstable/uncontrolled hypertension, defined by national recommendations.
  28. Subjects with pulmonary dysfunction or severe obstructive pulmonary disease.
  29. Subjects with active tuberculosis.
  30. Subjects with liver or renal insufficiency.
  31. Subjects with unstable endocrine disease, including unstable diabetes or thyroid disease.
  32. Subjects with active or .
  33. Subjects with clinically active infection of herpetic diseases, including herpes simplex virus, varicella zoster virus (VZV), cytomegalovirus (CMV) or EBV.
  34. Subjects with known history of ocular infection with herpes simplex virus.
  35. Subjects with active (extraocular) infection (requiring or not the prolonged or chronic use of antimicrobial agents).
  36. Immunocompromised subjects with previous solid organ or bone marrow transplant.
  37. Subjects who receive a less than 4 weeks prior to SPVN06 injection
  38. Subjects who were infected by COVID-19 less than 2 weeks prior to SPVN06 injection.
  39. Subjects who have recently received (less than 4 weeks) or plan to receive a COVID-19 vaccination.
  40. Incapacitated subjects, as defined by national laws.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Step 1 : SPVN06 dose 1

    Participants will receive a single subretinal injection of SPVN06 Dose 1 on Day 0.

    Drug: SPVN06

  • Experimental
    Step 1 : SPVN06 dose 2

    Participants will receive a single subretinal injection of SPVN06 Dose 2 on Day 0

    Drug: SPVN06

  • Experimental
    Step 1 : SPVN06 dose 3

    Participants will receive a single subretinal injection of SPVN06 Dose 3 on Day 0

    Drug: SPVN06

  • Experimental
    Step 2 : SPVN06 Dose Recommended 1

    Participants will receive a single subretinal injection of SPVN06 recommended dose 1 on Day 0

    Drug: SPVN06

  • Experimental
    Step 2 : SPVN06 Dose Recommended 2

    Participants will receive a single subretinal injection of SPVN06 recommended dose 2 on Day 0

    Drug: SPVN06

  • No intervention
    Step 2 : Control group

Interventions

  • DrugSPVN06

    AAV-RdCVF-RdCVFL

06

What researchers measure

Primary outcomes

  1. Evaluation of the safety and tolerability of a single injection of SPVN06 in subjects with advanced RCD, 12 months after administration of gene therapy.

    Incidence and severity of systemic and ocular AEs and SAEs

    Time frame: Baseline to 12 months after administration of gene therapy

Secondary outcomes

  1. Evaluation of the long-term safety and tolerability of a single injection of SPVN06 in subjects with advanced RCD, up to 5 years after treatment administration.

    Incidence and severity of systemic and ocular AEs and SAEs

    Time frame: up to 5 years after treatment

  2. Evaluation of viral shedding and bio-dissemination up to 1 year after treatment administration.

    Quantification of viral DNA copies in tears (viral shedding) and in blood (bio-dissemination)

    Time frame: up to 1 year after treatment

  3. Evaluation of the immune response against the viral vector and the transgene products of SPVN06 up to 5 years after treatment administration.

    Titration of total antibodies against the viral capsid

    Time frame: up to 5 years after treatment

  4. Evaluation of preliminary efficacy as assessed by visual acuity

    BCVA change from baseline (EDTRS chart)

    Time frame: up to 5 years after treatment

  5. Evaluation of preliminary efficacy as assessed by optical coherence tomography

    Anatomical change from baseline (SD-OCT)

    Time frame: up to 5 years after treatment

  6. Evaluation of preliminary efficacy as assessed by color vision

    Change from baseline of parameters collected by color vision assessment

    Time frame: up to 5 years after treatment

  7. Evaluation of preliminary efficacy as assessed by visual field

    Change from baseline of static perimetry, kinetic perimetry and microperimetry

    Time frame: up to 5 years after treatment

  8. Evaluation of preliminary efficacy as assessed by retinal sensitivity

    Change from baseline of parameters collected by full-field electroretinography

    Time frame: up to 5 years after treatment

  9. Evaluation of preliminary efficacy as assessed by retinal sensitivity

    Change from baseline of parameters collected by FST

    Time frame: up to 5 years after treatment

  10. Evaluation of preliminary efficacy as assessed by FAF

    Change from baseline of parameters collected by fundus autofluorescence

    Time frame: up to 5 years after treatment

  11. Evaluation of preliminary efficacy as assessed by quality of life

    Change from baseline of parameters collected by VFQ-25

    Time frame: up to 5 years after treatment

  12. Evaluation of preliminary efficacy as assessed by quality of life

    Change from baseline of parameters collected by ViSIO-PRO

    Time frame: up to 5 years after treatment

Other outcomes

  1. Exploratory objective - Exploration of biomarkers

    Collect and store urine and blood (in addition to the body fluids used for the assessment of viral shedding and bio-dissemination) for further exploration of biomarkers of medical interest not already identified at time of protocol submission.

    Time frame: up to 5 years after treatment

  2. Exploratory objective - Photoreceptor mosaic imaging

    Collect and analyze photoreceptor mosaic images using adaptive optics

    Time frame: up to 5 years after treatment

  3. Exploratory objective - Low luminance visual acuity (LLVA)

    ETDRS for distance vision

    Time frame: up to 5 years after treatment

07

Study locations

6 sites
08

References and documents

Publications

  • Clerin E, Yang Y, Pagan D, Achiedo S, Blond F, Millet-Puel G, Ait-Ali N, Harichane I, Degardin J, Cesar Q, Simonutti M, Bennett J, Zeitz C, Audo I, Cronin T, Leveillard T, Sahel JA. Combined Expression of hRdCVF and hRdCVFL Through AAV-Mediated Delivery for the Treatment of Retinitis Pigmentosa. Invest Ophthalmol Vis Sci. 2026 Mar 2;67(3):2. doi: 10.1167/iovs.67.3.2. PubMed 41769936 ↗
  • Marie M, Churet L, Gautron AS, Farjo R, Mizuyoshi K, Stevenson V, Khabou H, Leveillard T, Sahel JA, Lorget F. Preclinical safety and biodistribution of SPVN06, a novel gene- and mutation-independent gene therapy for rod-cone dystrophies. Gene Ther. 2025 Aug 4. doi: 10.1038/s41434-025-00556-3. Online ahead of print. PubMed 40759732 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Feb 2027, 46 months after the start.

Of 29 phase 1/2 interventional studies under Retinitis Pigmentosa, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 92. This study's planned 46 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Mar 1, 2023
StartActual
Apr 12, 2023
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2031
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05748873
Lead sponsor
SparingVision
Responsible party
Sponsor
First posted
Mar 1, 2023
Start date
Apr 12, 2023
Primary completion
Feb 2027 (estimated)
Completion
Feb 2031 (estimated)
Last update
May 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion